What is the 13F Pro Quality Score for NXTC?

13F Pro ranks NextCure, Inc. (NXTC) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View NXTC's current score at https://13fpro.ai/research/NXTC (free sign-up required for the full ranking).

Where does 13F Pro source NXTC data?

All NextCure, Inc. fundamentals and ownership data come directly from SEC EDGAR. NextCure, Inc. files with the SEC under CIK 1661059. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is NXTC in?

NextCure, Inc. (NXTC) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is NXTC research updated on 13F Pro?

NXTC's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

NextCure, Inc.(NXTC)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1661059 NXTC stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Limited institutional coverage

Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 24 institutional filers currently hold this stock.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

NXTC Stock Analysis & AI Quality Score

AI stock analysis and institutional research for NextCure, Inc. (NXTC), a Healthcare sector company. NXTC is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 24 institutional filers currently hold this stock. Based on the latest XBRL financial filings (Q1 2026), NextCure, Inc. reports net income of $-9.8M, free cash flow of $-13.4M. Top institutional holders of NXTC by reported 13-F value include Squadron Capital Management, Affinity Asset Advisors,, Ikarian Capital,, based on the most recent SEC filings. NXTC trades on the Nasdaq exchange and files with the SEC under CIK 1661059. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NXTC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for NextCure, Inc. directly from SEC EDGAR. NextCure, Inc.'s 13F Pro composite quality score has ranged between 7 and 38 since 2021, currently 9.2 — a declining long-term trajectory across 8 quarterly and live scoring snapshots.

Net Income

Q1 2026

$-9.8M

Free Cash Flow

Q1 2026

$-13.4M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

—FY 2023

FY19 $6.3MFY20 $22.4MFY21 —FY23 —

Net Income

+9.6% YoY

$-62.7MFY 2023

FY19 $-33.7MFY20 $-36.6MFY21 $-69.4MFY23 $-62.7M

Operating Income

+4.4% YoY

$-67.6MFY 2023

FY19 $-37.5MFY20 $-41.2MFY21 $-70.8MFY23 $-67.6M

EPS (Diluted)

+10.4% YoY

$-2.25FY 2023

FY19 —FY20 $-1.33FY21 $-2.51FY23 $-2.25

Total Assets

-47.2% YoY

$128.0MFY 2023

FY19 $356.2MFY20 $306.6MFY21 $242.4MFY23 $128.0M

Total Debt

—FY 2023

FY19 $6.7MFY20 $5.1MFY21 $0.00FY23 —

Op. Cash Flow

+7.5% YoY

$-53.0MFY 2023

FY19 $-35.6MFY20 $-45.0MFY21 $-57.3MFY23 $-53.0M

Metric	FY 2023	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Revenue	—	—	$22.4M +252.6%	$6.3M	—	—
Net Income	$-62.7M +9.6%	$-69.4M -89.6%	$-36.6M -8.5%	$-33.7M -48.0%	$-22.8M	—
Operating Income	$-67.6M +4.4%	$-70.8M -71.7%	$-41.2M -10.0%	$-37.5M -61.6%	$-23.2M	—
EPS (Diluted)	$-2.25 +10.4%	$-2.51 -88.7%	$-1.33	—	—	—
Total Assets	$128.0M -47.2%	$242.4M -21.0%	$306.6M -13.9%	$356.2M +141.3%	$147.6M	—
Total Debt	—	$0.00 -100.0%	$5.1M -22.9%	$6.7M +687.1%	$847.0K	—
Operating Cash Flow	$-53.0M +7.5%	$-57.3M -27.4%	$-45.0M -26.2%	$-35.6M -545.7%	$8.0M	—

AI Insight: NXTC Financial Trends

NextCure's equity base has eroded from $85M to $27M over eight quarters despite some recent volatility in quarterly losses.

• Equity declined from $85M in Q2 2024 to $27M in Q1 2026, a 68% reduction over eight quarters.

• Net losses ranged from $9M to $27M per quarter with Q2 2025 showing the largest loss at $27M.

• Operating cash flow remained consistently negative, ranging from $6M to $23M outflows quarterly.

⚠ Equity base now at $27M after consistent quarterly cash burn — runway increasingly constrained for pre-revenue biotech.

⚠ Q2 2025 spike in losses to $27M versus typical $9-12M quarterly burn suggests potential one-time charges or program costs.

AI Insight: NXTC Ratio Trends

NextCure's profitability deteriorated significantly, with ROE plunging from -61.1% in Q3 2024 to -146.7% in Q1 2026.

• ROE declined sharply from -61.1% in Q3 2024 to -146.7% in Q1 2026, indicating worsening shareholder returns.

• ROA fell from -51.1% in Q3 2024 to -75.2% in Q4 2025 before data became unavailable.

• ROIC data became unavailable after Q1 2025 when it reached -83.2%, suggesting continued operational challenges.

⚠ Data availability has become increasingly sparse across key profitability metrics in recent quarters.

⚠ The magnitude of negative returns suggests significant cash burn continues across the business.

Get alerted when NXTC's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for NextCure, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of NXTC

Squadron Capital Management LLC
$2.8M265,000 sh
Affinity Asset Advisors, LLC
$2.6M241,826 sh
Ikarian Capital, LLC
$2.5M238,303 sh
Sofinnova Ventures Inc
$2.4M222,654 sh
SILVERARC CAPITAL MANAGEMENT, LLC
$1.9M176,057 sh
PFIZER INC
$1.5M153,354 sh
Opaleye Management Inc.
$1.5M141,181 sh
AWM Investment Company, Inc.
$1.2M117,371 sh
Exome Asset Management LLC
$1.2M115,500 sh
BOOTHBAY FUND MANAGEMENT, LLC
$743.5K69,617 sh

Fund	Value	Shares
Squadron Capital Management LLC	$2.8M	265,000
Affinity Asset Advisors, LLC	$2.6M	241,826
Ikarian Capital, LLC	$2.5M	238,303
Sofinnova Ventures Inc	$2.4M	222,654
SILVERARC CAPITAL MANAGEMENT, LLC	$1.9M	176,057
PFIZER INC	$1.5M	153,354
Opaleye Management Inc.	$1.5M	141,181
AWM Investment Company, Inc.	$1.2M	117,371
Exome Asset Management LLC	$1.2M	115,500
BOOTHBAY FUND MANAGEMENT, LLC	$743.5K	69,617

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put NXTC on your watchlist

Track score changes the day NextCure, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is NXTC a good stock to buy?

13F Pro's AI-powered analysis of NextCure, Inc. (NXTC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NXTC are available on the NXTC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own NXTC?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NXTC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of NextCure, Inc.'s investment landscape.